Indian Court Rejects Bayer’s Plea to Halt Natco Sorafenib Exports
This article was originally published in PharmAsia News
Executive Summary
Bayer has suffered yet another setback in its long battle to defend its Nexavar patent in India. A recent decision permitted the local firm Natco to export a small quantity of sorafenib to Hisun of China.